MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Phase 2
Completed
Conditions
Meningitis, Meningococcal
Interventions
Biological: MenABCWY vaccine
Biological: rMenB+OMV NZ (Bexsero) vaccine
Biological: MenACWY (Menveo) vaccine
First Posted Date
2018-07-16
Last Posted Date
2020-02-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
520
Registration Number
NCT03587207
Locations
🇨🇿

GSK Investigational Site, Hradec Kralove, Czechia

Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)

Phase 2
Completed
Conditions
Infections, Bacterial
Interventions
First Posted Date
2018-06-26
Last Posted Date
2020-06-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT03568942
Locations
🇺🇸

GSK Investigational Site, La Mesa, California, United States

Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

Phase 1
Withdrawn
Conditions
Amyloidosis
Interventions
Drug: GSK3039294
Drug: Placebo
First Posted Date
2018-06-25
Last Posted Date
2018-10-09
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT03567499
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

Completed
Conditions
Herpes Zoster
Interventions
Other: Encoding of data collected in Zoster 006 and Zoster 022 studies
First Posted Date
2018-06-20
Last Posted Date
2020-04-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
26976
Registration Number
NCT03563183
Locations
🇬🇧

GSK Investigational Site, Newtonabbey, United Kingdom

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

Phase 1
Completed
Conditions
Infections, Bacterial
Interventions
First Posted Date
2018-06-19
Last Posted Date
2021-04-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
25
Registration Number
NCT03562117
Locations
🇺🇸

GSK Investigational Site, Orlando, Florida, United States

A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Mepolizumab 100 milligrams
Drug: Placebo
Drug: Salbutamol
First Posted Date
2018-06-19
Last Posted Date
2022-10-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT03562195
Locations
🇨🇳

GSK Investigational Site, Tianjin, China

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

Phase 2
Completed
Conditions
Tuberculosis
Interventions
Drug: GSK3036656
Drug: Rifafour e-275
First Posted Date
2018-06-15
Last Posted Date
2023-10-26
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
76
Registration Number
NCT03557281
Locations
🇿🇦

GSK Investigational Site, Cape Town, South Africa

NUCALA® Special Drug Use Investigation (EGPA, Long-term)

Conditions
Churg-Strauss Syndrome
Interventions
Drug: Nucala
First Posted Date
2018-06-14
Last Posted Date
2018-09-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT03557060
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

Phase 1
Completed
Conditions
Rhinitis
Interventions
Drug: Levocetirizine IRT 5 mg
Drug: Levocetirizine ODT 5 mg
First Posted Date
2018-06-14
Last Posted Date
2020-06-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
72
Registration Number
NCT03555890
Locations
🇯🇵

GSK Investigational Site, Fukuoka, Japan

A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)

Phase 2
Completed
Conditions
Congestion, Nasal
Interventions
Device: Breathe Right Tan (small/medium) nasal strips
Other: Placebo nasal strip
First Posted Date
2018-06-07
Last Posted Date
2018-09-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
130
Registration Number
NCT03549130
Locations
🇺🇸

Concentrics Research, Indianapolis, Indiana, United States

🇺🇸

TKL Research Inc, Paramus, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath